Differential Expression of Immune Checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on Circulating Natural Killer Cells - Insights from Healthy Donors Compared to Gastric Cancer Patients.

INTRODUCTION

The complex, multifactorial nature of gastric cancer presents significant challenges in the development of effective immunotherapies. Targeting immune checkpoints has emerged as a promising strategy, with blockade therapies demonstrating clinical success. However, resistance in a subset of patients emphasizes the need for alternative approaches. Exploration of novel immune checkpoints, particularly on natural killer (NK) cells, could enhance the efficacy and potency of immunotherapy, offering new avenues for overcoming resistance and improving patient outcomes. NK cells are crucial in the primary defense against viral infections, tumor development, and metastasis. The cytotoxic function of NK cells is finely regulated by a complex array of activating and inhibitory receptors, including checkpoint receptors. Malignantly transformed cells can impair NK-cell activity by expressing soluble or membrane-bound checkpoint ligands, thereby modulating immune responses to support tumor progression.

METHODS

To investigate this dilemma, we simulated in vitro activation by NK-cell co-incubation with K562 cells and analyzed expression of TIM-3, LAG-3, TIGIT, and Siglec-7. After that, we analyzed the checkpoint expression of circulating NK cells from 35 healthy donors and compared it to their expression in patients with gastric cancer (n = 21) using flow cytometry.

RESULTS

In healthy donors, we observed that 25-97% of all circulating NK cells expressed TIM-3, TIGIT and Siglec-7, while only a small fraction of 0.6% expressed LAG-3. Co-incubation of peripheral blood mononuclear cells from healthy donors with K562 cells resulted in heightened expression levels of TIM-3 and TIGIT on NK cells. Conversely, NK cells in patients with gastric cancer showed an increased LAG-3 and reduced Siglec-7 expression.

CONCLUSION

Our findings suggest the potential of LAG-3 as a next-generation checkpoint molecule, alongside Siglec-7. Especially targeting the sialic acid-Siglec-7 axis may offer promising therapeutic strategies for various cancer types in the future.